Bristol-Myers Buying Karuna Signals A Biotech Boom Ahead: Jefferies

Bristol-Myers Squibb is buying Karuna Therapeutics for $14 billion. Karuna Therapeutics Inc stock jumped nearly 50% on Friday. Jefferies analyst Michael Yee shares his view on biotech stocks.